Loading...

REPL REPLIMUNE GROUP INC US FDA Inspections 8-K Filing

RPLM

RPL

REPLIMUNE GROUP INC

(REPL)

2025 8-K

Show Summary

Summary

Pre-Market Approval

Investor Meetings

Financial Statements

Board Appointment

Financial Results

Warrant Adjustment

Stock Offering Update

Financial Results

Financial Results and Corpo...

Securities Purchase Agreement

Data Updates and Topline Re...

Data Updates Announcement

Financial Results Announcement

Executive Leadership Transi...

Results of Operations and F...

Clinical Data Presentation

Loan Agreement Amendment

Data Updates and Developmen...

Earnings Reports

Appointment of CFO

Annual Meeting of Stockholders

Sales Agreement with Leerin...

Financial Results and Colla...

Appointment of Director

Financial Results and CFO R...

Regulation FD Disclosure

Earnings Reports

Management Changes

External Links:

On July 21, 2025, Replimune Group, Inc. received a Complete Response Letter from the FDA regarding its Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for treating advanced melanoma. This indicates that the FDA has not approved the application yet.

AI Assistant

REPLIMUNE GROUP INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.